Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects.
We examined 516G>T polymorphisms at the gene encoding the cytochrome P450 in 100 human immunodeficiency virus-positive subjects who were receiving efavirenz (EFV). Elevated plasma EFV concentrations were found in 40% of subjects with the polymorphic homozygous genotype and 19% of subjects with the heterozygous genotype. Conversely, 20% of subjects with the wild-type genotype had subtherapeutic concentrations of EFV. CYP2B6-516 genotyping may help to identify subjects who have plasma EFV concentrations that are outside of the therapeutic range.
Rodriguez-Novoa
Sonia
S
Pharmacokinetic Unit, Hospital Carlos III, Madrid, Spain.
Barreiro
Pablo
P
Rendón
Ana
A
Jiménez-Nacher
Inmaculada
I
González-Lahoz
Juan
J
Soriano
Vincent
V
D000328:Adult; D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000235:genetics*; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D007527:Isoenzymes / Q000235:genetics; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000009:adverse effects / Q000097:blood* / Q000493:pharmacokinetics*; D020641:Polymorphism, Single Nucleotide
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D007527:Isoenzymes; D010078:Oxazines; D003577:Cytochrome P-450 Enzyme System; C098320:efavirenz